Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma

logos EORTC and Pierre Fabre

Pierre Fabre and the European Organisation for Research and Treatment of Cancer (EORTC) today announced the screening of the first patient with a resected stage II BRAF-mutant melanoma for the phase III study COLUMBUS-AD (NCT05270044; EORTC-2139-MG).

COLUMBUS-AD is a pioneering study to evaluate whether the combination of BRAF and MEK inhibitors encorafenib (Braftovi®) and binimetinib (Mektovi®) can prolong recurrence-free survival (RFS) and improve distant metastasis-free survival (DMFS) and overall survival (OS) as compared to placebo in participants with surgically resected stage IIB-C BRAF V600E/K-mutant cutaneous melanoma.

“Pierre Fabre’s partnership with EORTC is now accelerating with the opening of COLUMBUS-AD”, said Dr Deborah Szafir, Executive Vice President, Head of Medical and Patient Consumer Division at Pierre Fabre. “Building on the clinical benefits that our medicines have demonstrated in advanced disease, we are eager for patients with a BRAF-mutated tumour to explore the adjuvant setting in an earlier stage of the disease as the unmet medical need remains high.”

Despite the remarkable progress made in the treatment of advanced melanoma activating the BRAF mutation, unfortunately there remains a high unmet need in earlier stages of the disease. It is estimated that 18% of stage IIB and 25% of stage IIC patients die from melanoma within 10 years from diagnosis.

“The screening of patients for COLUMBUS-AD focuses on patients with surgically resected high-risk IIB-C BRAF V600E/K-mutant cutaneous melanoma”, said study coordinator assoc. prof. Dr. Alexander C.J. Van Akkooi, MD PhD, from the Melanoma Institute Australia (MIA) and past chairman of the EORTC Melanoma Group. “It is essential to test the tumour as early as possible for BRAF mutation, so that eligible patients can get a chance to participate into COLUMBUS-AD”.

Approximately 815 patients will be enrolled in COLUMBUS-AD. More than 160 sites in up to 25 countries worldwide will participate in the study.

Patients included in the study must have undergone resection of a stage IIB-C melanoma with a BRAF V600E/K mutation, confirmed on resected tumour sample by a central laboratory, and a negative result on sentinel node biopsy. Patients must also have fully recovered from the surgery, have a good performance status (ECOG 0/1), and adequate hematologic, hepatic, cardiac, coagulation and renal functions.

Patients will receive encorafenib and binimetinib or placebo for up to 12 months. They will be followed-up monthly during the treatment period, then every 3 months up to year 3, and then at regular intervals. The participants will be followed-up for 10 years in total.

Pierre Fabre has a long-standing commitment to the melanoma community and takes a unique holistic approach to skin health with expertise in oncology, dermatology and dermo-cosmetics. EORTC, a unique academic clinical research organisation uniting clinical cancer research experts across the globe, shares Pierre Fabre’s commitment to improving the standard of cancer treatment for patients.

About Melanoma

Melanoma develops when unrepaired DNA damage to skin cells triggers mutations that may lead them to multiply and form malignant tumours.1 There are about 324,000 new cases of melanoma diagnosed worldwide each year, approximately half of which have BRAF mutations, a key target in the treatment of metastatic melanoma.2,3,4 By 2025, the number of cases is expected to increase to over 340,000.5

About the EORTC

The European Organisation for Research and Treatment of Cancer (EORTC) is a non-governmental, non-profit organisation, which unites clinical cancer research experts, throughout Europe, to define better treatments for cancer patients to prolong survival and improve quality of life. Spanning from translational to large, prospective, multi-centre, phase III clinical trials that evaluate new therapies and treatment strategies as well as patient quality of life, its activities are coordinated from EORTC Headquarters, a unique international clinical research infrastructure, based in Brussels, Belgium.

For further information, please visit the EORTC website:

About encorafenib (Braftovi®) and binimetinib (Mektovi®)

Encorafenib is an oral small-molecule BRAF kinase inhibitor and binimetinib is an oral small-molecule MEK inhibitor that targets key enzymes in the MAPK signalling pathway (RAS-RAF-MEK-ERK). Inappropriate activation of proteins in this pathway has been shown to occur in many cancers, including melanoma, colorectal cancer, non-small-cell lung cancer, thyroid and others.

Pierre Fabre has exclusive rights to develop and commercialise Braftovi® and Mektovi® worldwide, except in the US and Canada, where Pfizer (Array BioPharma) retains exclusive rights; Israel, where Medison has exclusive rights; Japan and South Korea, where Ono Pharmaceutical has exclusive rights to commercialise both products; and Latin America, Africa and Middle East where both products have been sub-licensed to Pfizer.

Pierre Fabre is the sponsor of the COLUMBUS-AD Phase III study. The overall development of Braftovi® and Mektovi® is driven in partnership with Pfizer in diverse indications.

About Pierre Fabre Oncology

Pierre Fabre is a French health and beauty care company with 35-years of experience in innovation, development, manufacturing and commercialization in oncology, and the 2nd largest dermo-cosmetics laboratory in the world, the 2nd largest private French pharmaceutical group and the market leader in France for products sold over the counter in pharmacies.

Its portfolio includes several medical franchises and international brands including Pierre Fabre Oncology, Pierre Fabre Dermatology, Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Naturactive, Pierre Fabre Oral Care.

The company has recently reaffirmed oncology as one of its main R&D and commercial priorities, focusing on targeted therapies, biotherapies and immuno-oncology. Its therapeutic areas include unmet medical needs, and cover colorectal, breast, lung cancers, melanoma and pre-cancerous conditions such as actinic keratosis.

In 2021, Pierre Fabre generated €2.5 billion in revenues, 66% of which came from international sales.

Established in the South-West of France since its creation, the Group manufactures over 95% of its products in France and employs some 9500 people worldwide. Its products are distributed in about 115 countries.

Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognised public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan.

Ecocert Environnement had assessed the Groups corporate social and environmental responsibility approach in accordance with the ISO 26000 sustainable development standard since 2019, and confirmed its“Excellence”level in 2021.



[1] Neoplasma. 2016;63(4):510-7. doi: 10.4149/neo_2016_403.
[2] American Cancer Society. What Causes Melanoma Skin Cancer. Available at: Accessed May 2021.

[3] International Agency for Research on Cancer. Melanoma of skin. Available at: Accessed May 2021.

[4] Klein O, et al. Eur J Cancer 2013;49:1073–1079.

[5] Melanoma UK. 2020 Melanoma Skin Cancer Report. Available at: 2020 MELANOMA SKIN CANCER REPORT | Melanoma UK. Accessed May 2021.




Pierre Fabre


Back to news list

Related News

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC